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SUMMARY
Background—Renal failure occurs in 5–18% of sickle cell disease (SCD) patients and is
associated with early mortality. At risk SCD patients cannot be identified prior to the appearance
of proteinuria and the pathobiology is not well understood. The MYH9 and APOL1 genes have
been associated with risk for focal segmental glomerulosclerosis and end-stage renal disease in
African Americans.
Methods—We genotyped 26 SNPs in MYH9 and 2 SNPs in APOL1 in 521 unrelated adult (18–
83 years) SCD patients screened for proteinuria. Using logistic regression, SNPs were evaluated
for association with proteinuria.
Results—Eight MYH9 SNPs and one APOL1 SNP were nominally associated with proteinuria.
Six SNPs remained significant after multiple testing correction (p < 0.0025), and a risk haplotype
was associated with proteinuria (p=0.001). Using multiple regression, association with APOL1
diminished in the presence of MYH9 SNPs. Glomerular filtration rate was negatively correlated
with proteinuria (p < 0.0001), and was nominally associated with MYH9 and APOL1 in age-
adjusted analyses.
Conclusion—Our data provide insight into the pathobiology of renal dysfunction in SCD,
suggesting that MYH9 is more strongly associated than APOL1. These data also provide the
opportunity for early identification of patients at risk and new therapeutics.
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African Americans have an increased risk for chronic kidney disease (CKD), including HIV-
associated nephropathy (Kopp and Winkler 2003), focal segmental glomerulosclerosis
(FSGS) (Kitiyakara, et al 2004), and hypertensive nephrosclerosis (Toto 2004). These
conditions can all lead to irreversible end-stage renal disease (ESRD). African Americans
also have a disproportionate risk for developing ESRD compared with whites. The
cumulative lifetime risk for ESRD for a 20 year old African American woman is 7.8%,
compared to a 1.8% equivalent risk for white women (Kiberd and Clase 2002). Even after
adjusting for socioeconomic and other non-genetic risk factors, the relative risk of
developing ESRD is still 1.9 times higher in African Americans when compared to whites of
the same age (Powe 2003). This suggests that genetic factors contribute to this
disproportionate risk of developing ESRD in African Americans. Recently, using the
strategy of mapping by admixture linkage disequilibrium (MALD), Kopp et al. and Kao et
al. identified MYH9 as one of the genes underlying the ethnicity-driven health disparity in
both FSGS and ESRD respectively (Kao, et al 2008, Kopp, et al 2008). Variation in MYH9
was estimated to account for about 70% of ESRD in non-diabetic African American patients
(Bostrom and Freedman 2010). Upon further examination, however, it was suggested that
the true association with ESRD was with the apolipoprotein L-1 (APOL1) gene, due to both
the stronger statistical association with that gene and the lack of identification of causal
functional variants in the MYH9 gene (Genovese, et al 2010a, Genovese, et al 2010b, Tzur,
et al 2010). The original association with MYH9 was attributed to both the strong linkage
disequilibrium (LD) between MYH9 and APOL1 and the insufficient coverage on genome
wide SNP chips for the African diversity.
Sickle cell disease (SCD) comprises a group of disorders in which sickle hemoglobin (HbS)
is present in red cells due to either homozygosity for the hemoglobin beta chain allele
encoding the HbS form or double heterozygosity for the gene variant encoding HbS and
another hemoglobin gene variant encoding a beta chain that interacts with HbS, such as HbC
or HbOarab to produce clinical features. SCD nephropathy affects a minority of patients with
SCD but is a major risk factor for early mortality (Platt, et al 1994). SCD nephropathy is a
clinically well characterized entity that includes papillary necrosis, hyposthenuria, impaired
renal acidification, proteinuria, hematuria, supranormal proximal tubular function, and renal
failure (Stuart and Nagel 2004). In adults with SCD, the incidence of micro- and macro-
albuminuria has been estimated to occur in 68% of patients, while macroalbuminuria alone
occurs in 26% of patients (Guasch, et al 2006). Mortality due to chronic renal failure in
adult SCD patients is about 10.5% (Platt, et al 1994).
Because of the strong linkage disequilibrium in the region of chromosome 22 which
contains both the MYH9 and APOL1 genes, we have genotyped SNPs in both genes in order
to determine if variants in either gene may be associated with risk of SCD nephrophathy.
METHODS
Data set
Five hundred twenty-one unrelated patients were enrolled as part of a multicenter study of
genetic associations with clinical outcomes in SCD. Participating institutions were Duke
University, University of North Carolina at Chapel Hill, East Carolina University and
Emory University Sickle Cell Centers. Patients enrolled were between ages 18–83 years.
Diagnoses included Hb SS (n=452), Hb Sβ0 thalassemia (n=18), Hb Sβ+ thalassemia (n=17),
and Hb SC (n=34). Mean and median ages were 33.9 and 32.0 years, respectively. Almost
all patients (498, or 98.81%) identified themselves as non-Hispanic African-Americans, 2
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(0.40%) as Hispanic Blacks, 1 (0.20%) as a non-Hispanic Caucasian, and 3 (0.60%) as
Hispanic Caucasians. Two hundred thirty subjects (44.15%) were male.
All patients provided informed consent and were enrolled for the genetic study according to
Institutional Review Board-approved procedures. Blood samples were obtained by routine
phlebotomy at steady state. All patients were also evaluated for proteinuria by a standard
urine dipstick analysis. Individuals were categorized as having proteinuria if the dipstick
analysis results were 1+ through 4+, and as not having proteinuria if the dipstick analysis
demonstrated no protein or trace amounts. Because of the historical nature of the data set, it
was not possible to obtain a more accurate measure of proteinuria such as collection of 24
hour urine samples. Despite there being more accurate methods of detecting proteinuria, the
sensitivity and specificity of dipstick to detect microalbuminuria has been estimated to be
70% and 83%, respectively (Sarafidis, et al 2008). The prevalence of proteinuria in our data
set was 26.9%, which is consistent with the 20–30% previously reported in SCD (Pham, et
al 2000). Our genetic analysis used the occurrence of proteinuria as our dependent variable,
as we did not have complete information regarding SCD nephropathy in our data set and
proteinuria is a key component of the nephropathy disease process.
Genotyping
Twenty-six haplotype tagging SNPs in MYH9 were selected using LDSelect v1.0 (Carlson,
et al 2004), based on data from the Yoruban population in the HapMap project
(www.hapmap.org). In order to minimize redundancy among SNPs in high LD, we selected
a single SNP to represent each haplotype block, as defined by r2 > 0.64. SNPs were also
required to have a minor allele frequency > 0.05 so that there would be reasonable power to
detect associations in our data set. Subsequent to our examining the MYH9 gene, it was
reported that the true association with ESRD in African Americans was due to the APOL1
gene (Genovese, et al 2010a, Genovese, et al 2010b, Tzur, et al 2010). Thus, we also typed
two SNPs (rs73889319 and rs71785313) in APOL1 that had been identified as being most
strongly associated with focal segmental glomerulorsclerosis (Genovese, et al 2010a).
DNA was extracted from study participant blood samples by standard procedures and
deposited in the DNA Bank and Tissue Repository of the Center for Human Genetics at
Duke University. SNP genotyping was performed using Taqman Predesigned Genotyping
Assays (Applied Biosystems, Foster City, CA). The polymerase chain reaction (PCR) was
carried out on an ABI 9700 dual 384-well Geneamp PCR system (Applied Biosystems).
Each well contained a total of 3ng genomic DNA. Analysis of genotype was done with an
ABI Prism 7900 Sequence Detection System (Applied Biosystems).
Quality control measures applied for all genotyping assays included the genotyping of a
series of blinded duplicate samples and Centre d’Etude du Polymorphism Humain (CEPH)
controls. To pass quality control, all duplicate samples in an assay had to match 100%.
Further, we required that 95% of the genotypes for each assay could be called with certainty
to be considered for statistical analysis. The sample size for each SNP varied slightly due to
differences caused by missing genotype data.
Statistical Analysis
The 26 SNPs in the MYH9 gene and 2 SNPs in the APOL1 gene were assessed for Hardy-
Weinberg Equilibrium (HWE) using exact tests implemented in the Genetic Data Analysis
program (Zaykin, et al 1995) prior to analysis for association with proteinuria. None of the
SNPs deviated significantly from HWE, and thus all 28 SNPs were subsequently analyzed.
Pairwise linkage disequilibrium measures (r2) between markers were calculated using the
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Graphical Overview of Linkage Disequilibrium (GOLD) software (University of Michigan,
MI).
We constructed contingency tables and tests of association for both genotypes and alleles by
occurrence of proteinuria using PROC FREQ (SAS System v9.1, Cary, NC). Logistic
regression was performed to determine the effect of genotype on proteinuria and the effect
of alleles on proteinuria using PROC LOGISTIC (SAS System v9.1). Generalized linear
models were used to assess the effect of genotype on glomerular filtration rate using PROC
GLM (SAS System v9.1). Haplotype associations were explored using functions from the
haplo.stats program implemented in R, which accounts for linkage phase ambiguity in
unrelated subjects (Lake, et al 2003, Schaid, et al 2002). Haplotype frequencies were
estimated using the haplo.em function, and regression analysis to test for association
between haplotypes and proteinuria was generated using the haplo.glm function.
We corrected for multiple testing using the method described by Li and Ji (Li and Ji 2005),
which constructs an effective number of tests (Meff) based on the LD structure of the SNPs.
We then applied the Bonferroni method to generate the corrected threshold for significance
testing using the effective number of tests. The corrected significance level for association
testing in our analysis was (0.05/Meff = 0.0025).
RESULTS
Of 521 SCD patients studied, 140 had proteinuria, while 381 did not have proteinuria. On
average, subjects with proteinuria were 6 years older than subjects without proteinuria (p <
0.0001), indicating that older patients were more likely to have proteinuria, as has been
noted in other studies (Guasch, et al 2006). In our data set, the odds of having proteinuria
increased by 1.04 (4.2%) for every one year increase in age (starting at age 18). Because of
this strong association between age and proteinuria, models examining the effect of
genotype on proteinuria were adjusted for age.
Analysis of our data set using the genotype test resulted in identification of 9 SNPs that were
nominally associated with proteinuria (p < 0.05); 6 of these SNPs met the corrected multiple
comparison threshold (p < 0.0025) (Fig. 1). One SNP was in the APOL1 gene (rs73885319,
p = 0.0022) and the remaining five SNPs were in the MYH9 gene (rs11912763, p = 0.0003;
rs16996648, p = 0.0025; rs1557529, p = 0.0019; rs8141189, p = 0. 001; rs16996672, p =
0.0001; Table 1). The APOL1 SNP which met the multiple comparison threshold, is a
missense mutation (S342G) which is in strong LD with another missense mutation (I384M)
that was not typed in this data set. Those two SNPs have been previously referred to as the
G1 tag that was associated with FSGS (Genovese, et al 2010a). Among the MYH9 SNPs
which met the multiple comparison threshold, rs5750248 and rs11912763 were identified
previously as representing the S-1 and F-1 risk haplotypes, respectively, that were very
strongly associated with kidney disease among African Americans and Hispanics (Behar, et
al 2010, Nelson, et al 2010). Despite our attempt to reduce LD in the MYH9 gene by
selecting haplotype tagging SNPs from the Yoruba population, there was some evidence of
LD in our own data set. One of the most significant SNPs, rs11912763, was in high LD (r2
=0.72) with rs16996648 and in moderate LD (r2 =0.57) with rs5756152. These correlations
are reflected in the correlation among the association results, whereby both rs11912763 and
rs16996648 were significantly associated with proteinuria, and rs5756152 approached
significance.
Among the six SNPs that met the multiple testing correction for significant association with
the occurrence of proteinuria, the frequency of proteinuria among the individuals who were
homozygous for the risk genotype ranged from 40% to 50%, as compared to the frequency
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of proteinuria among the individuals who did not have that genotype which ranged from
20% to 30%. Odds ratios for specific genotype comparisons are shown in Table 1.
In order to reduce the dimensionality of the SNPs in the MYH9 gene, we performed
haplotype association analysis, using the 8 SNPs in the MYH9 gene that were nominally
significant. This analysis revealed that the risk haplotype (including the risk allele for all 8
SNPs) was the second most prevalent haplotype for MYH9 in our study population. About
15% of the subjects in our data set had this haplotype, which was also significantly
associated with proteinuria (p = 0.001), such that those with the risk haplotype were about
2.7 times as likely to have proteinuria as those with the most frequent haplotype; which had
a prevalence of 20%. Those with the risk haplotype were also 1.6 times more likely to have
proteinuria as those with rarer haplotypes, which were grouped together for the purpose of
analysis. Analysis by haplotype was also adjusted for age, since age was significantly
associated with proteinuria (p = 0.00001).
Given reports that SCD patients with a more severe form of the condition (Hb SS and Hb
Sβ0) have a higher prevalence of proteinuria than other SCD forms (Guasch et al, 2006), we
decided to perform a second analysis of only these individuals and repeat the tests for
association. Using the genotype test, the results were similar. Eight SNPs were nominally
significant (p < 0.05), with 4 reaching the corrected multiple comparison threshold (p <
0.0025; rs73885319(APOL1), rs11912763 (MYH9), rs8141189(MYH9) and
rs16996672(MYH9)). Hb SS and Hb Sβ0 individuals make up the majority (90.38%) of our
data set, which likely explains the similarity to the results in the overall data set.
Because of the known relationship between proteinuria and glomerular filtration rate (GFR),
we also examined this relationship in our data set and found that GFR was inversely
correlated with proteinuria (r = −0.25, p < 0.0001), such that for every one unit decrease in
GFR, the odds of having proteinuria increases (OR=1.03). Further, we examined whether or
not the APOL1 and MYH9 SNPs were associated with GFR, but we did not detect any
associations in unadjusted analyses. However, when we controlled for age, we observed
nominal associations with rs73885319 (APOL1, p = 0.01), rs11912763 (MYH9, p = 0.01),
rs4820234 (MYH9, p = 0.05), and rs933224 (MYH9, p = 0.004). When we performed
haplotype analysis for the MYH9 gene (as defined above) and controlled for age, we did not
detect a significant association with GFR, although there was a trend (p=0.08).
Given that the previous work in non-SCD populations were providing stronger evidence for
association between ESRD and APOL1 rather than MYH9 (Genovese, et al 2010a,
Genovese, et al 2010b, Tzur, et al 2010), we decided to do multiple regression analyses to
determine if we could sort out this question in our own data set. Thus, we repeated the
analyses where we predicted proteinuria as a function of each of the eight nominally
significant MYH9 SNPs (Table 1), while controlling both for age and rs73885319 (the
APOL1 SNP significant with multiple testing correction in our data set). Unlike in the
previous reports (Genovese, et al 2010a, Genovese, et al 2010b, Tzur, et al 2010), in our
data set, we observed that three of the MYH9 SNPs remained nominally significant
predictors of proteinuria, even when rs73885319 was a co-variate. In these multiple
regression analyses, the most significant association in the MYH9 gene remained with
rs16996672 (p = 0.007). Furthermore, in these analyses, the evidence for association with
APOL1 rs73885319 dropped, such that it only remained nominally significant (p = 0.01) for
the analysis with a single MYH9 marker, rs5756129. In all other analyses that included any
of the other seven MYH9 SNPs (Table 1), the evidence for association between rs73885319
disappeared (data not shown). Thus, in the SCD population, it appears that the evidence for
association is stronger for the MYH9 gene than it is for the APOL1 gene.
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Nephropathy is a major risk factor for early mortality in SCD (Platt, et al 1994). Early
detection of those at risk for this outcome and understanding the mechanism of disease are
both required in order to develop therapy that can reduce morbidity and mortality. Thus
identification of SNPs in MYH9 and APOL1 that are significantly associated with
proteinuria is quite intriguing. Although originally the association with ESRD had been
detected with the MYH9 gene in non-SCD populations (Kao, et al 2008, Kopp, et al 2008),
subsequent work has suggested that this association is likely due to a genetic “hitchhiking”
effect with the APOL1 gene, due to the strong LD between these two genes on chromosome
22 and the selective pressures believed to have perpetuated certain genetic variants of
APOL1 (Genovese, et al 2010a, Genovese, et al 2010b, Tzur, et al 2010). Our analysis in a
SCD study population provides stronger evidence for association with the MYH9 gene, in
contrast to these studies. The discrepancies between our results and the previous ones
highlight the challenges faced when attempting to identify genes associated with complex
disease phenotypes. Until variants are identified which clearly contribute in some functional
manner to the disease phenotype, it is difficult to discern which SNP or variant, or in this
case even which gene, is the causal culprit.
APOL1 is associated with resistance to Trypanosoma brucei, a common African parasite,
and it is believed that this role in host immunity has contributed to the selective pressures on
that gene and the surrounding region. Despite this intriguing population genetics story, it
remains to be seen how APOL1 directly contributes to kidney disease. Based on our current
analyses, MYH9 is a stronger candidate for association with SCD nephropathy and although
causal variants and mechanisms remain to be elucidated, MYH9 is a stronger biological
candidate, as well. MYH9 encodes the heavy chain of non-muscle myosin IIA and in
combination with actin, talin, α-actin-4, and vinculin, make up the cytoskeleton of the
podocyte - the cells lining the visceral surface of Bowman’s capsule in the kidney- foot
process (Drenckhahn and Franke 1988). This cytoskeleton is joined to the slit membrane-
“filtration pore” proteins by adaptor proteins such as zonula occludens-1 (ZO-1), and the
proper functioning of the slit membrane, and the ability to keep larger molecules like
proteins from being filtered depends on cytoskeletal integrity. Therefore, our identification
of the MYH9 gene as significantly associated with proteinuria supports previous
observations suggesting that development of proteinuria in SCD may involve the podocyte
cytoskeleton. Aslan et al. showed that nitration of three tyrosine residues (Tyr91, Tyr198,
Tyr240) of actin in the podocyte cytoskeleton modified actin assembly, causing alterations in
cytoskeletal polymerization (Aslan, et al 2003). This nitration is due to increased expression
of inducible nitric-oxide synthase (NOS2) caused by chronic ischemia-reperfusion injury in
SCD (Aslan, et al 2003, Vinas, et al 2007). The alteration in cytoskeletal polymerization
may cause a redistribution of the tight junction protein ZO-1 and could lead to proteinuria
(Macconi, et al 2000). However, once podocyte damage has occurred, other mechanisms,
possibly involving angiotensin II (Durvasula, et al 2004) and TGF-β (Schiffer, et al 2001),
could contribute to further damage and lead to apoptosis of podocytes. Thus, there seems to
be a continuum of glomerular damage, as have been suggested by Guasch et al (Guasch, et
al 1997).
Although our analysis showed a strong association between MHY9 and APOL1
(rs73885319) with proteinuria, the association with GFR was not as strong. Previous studies
have suggested that GFR is not a good indicator of early glomerular damage, and simple
measurement of GFR may fail to indicate significant early loss of glomerular function
(Guasch et al, 1996). However, both micro- and macroalbuminuria have been found to be
quite sensitive markers of glomerular function (Guasch, et al 1996). Thus, our finding that
MYH9 and APOL1 genotype were not as strongly associated with GFR is consistent with
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previous data. We therefore hypothesize that the MYH9 gene is likely to be associated with
early damage to the glomerulus, while polymorphisms of other genes, such as bone
morphogenetic protein receptor 1B (BMPR1B), found to be associated with GFR in SCD by
Nolan and colleagues (Nolan, et al 2007), may be implicated in later stages of kidney
damage. Although we tested for association with the two most significant BMPR1B SNPs
from the Nolan findings (rs2240036 and rs4145993), neither were associated with
proteinuria or GFR in age-adjusted analyses, suggesting that this gene may not be vital in
the development of early glomerular damage but may contribute more generally to renal
damage in SCD. We did observe nominal evidence for association with a different BMPR1B
SNP (rs1434536) and proteinuria in our data set (p=0.004, age-adjusted). To further
investigate a possible connection between BMPR1B and MYH9, we performed regression
analyses including BMPR1B SNPs (rs1434536, rs2240036 and rs4145993) and the MYH9
haplotype in the models and controlled for age. In all these analyses, MYH9 risk haplotype
remained a significant predictor of proteinuria and was only borderline associated with GFR.
None of the BMPR1B SNPs were associated with proteinuria or GFR when the MYH9
haplotype was included in the model, suggesting that MYH9 is likely the more important
contributor to these processes, at least in our data set.
Early intervention in patients who are likely to develop SCD nephropathy is very important,
because by 15 years of age, enough damage may have been done to the kidneys to ensure
progression to irreversible hyposthenuria (Saborio and Scheinman 1999) and eventual renal
failure. Thus, identification of a risk haplotype can potentially become part of a screening
tool to identify SCD patients who are at higher than average risk of developing SCD
nephropathy. The parameters GFR and albuminuria have been found to be independent
predictors of progression to ESRD and, when combined, show a better predictive value than
they do individually (Hallan, et al 2009). This suggests that both the MYH9 and BMPR1B
genes may interact to cause kidney damage which progresses to ESRD. It is tempting to
hypothesize that these genes may be potentially useful in the creation of a prognostic tool to
identify SCD nephropathy patients who are at risk of progressing to ESRD, so that
appropriate prevention strategies can be implemented. As yet, however, we do not know
what therapies are likely to be efficacious. Specific therapies aimed at reducing damage to
podocyte cytoskeletal structures could potentially become new therapies for SCD
nephropathy. Angiotensin converting enzyme (ACE) inhibitors, already used in a small
study of SCD patients, have been found to bring about proper distribution of ZO-1 proteins
and reduce proteinuria (Falk, et al 1992, Macconi, et al 2000). Other potential therapeutic
agents might include antagonists of TGF-β and agents that block maladaptive nitration of
podocyte cytoskeleton proteins such as actin.
Kopp et al. (Kopp, et al 2008) identified 9 SNPs that were strongly associated with focal
segmental glomerulosclerosis, and also found a very prevalent risk haplotype in their data
set. Of the SNPs we genotyped, five coincided with those genotyped by Kopp et al., and two
among these were significant in both data sets, despite the fact that our dataset and analyses
differ in several critical respects from those of the 2008 report. These differences include
patient population, the type of renal dysfunction studied, and how multiple testing
adjustments were made. The study by Kopp and colleagues was a case/control study in
which cases were drawn from a population of European Americans and African Americans
who had biopsy confirmed idiopathic or HIV associated focal segmental glomerulosclerosis,
while controls were drawn from the same ethnic groups and had either normal or
supernormal renal function. Although Kopp et al. applied the Bonferroni correction for
multiple testing, the LD pattern among the SNPs they genotyped was not considered in their
analysis; consequently, the SNPs making up the risk haplotype were mostly in the same LD
bin, and therefore mostly redundant. In contrast, we applied a fairly stringent threshold for
multiple testing, taking into consideration the LD pattern of the SNPs examined in order to
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determine an effective number of tests before applying the Bonferroni correction, and we
thereby found that several SNP associations withstood this stringent correction threshold.
Perhaps the largest limitation of our study was the use of a crude measure of proteinuria
(dipstick analysis). However, it is important to note that our approach would have
potentially misclassified individuals with microalbuminuria as not having proteinuria and
this would have weakened, not strengthened, any associations we have currently presented.
Thus, despite there being more precise measures of kidney function, we do not believe that
our phenotyping method resulted in a false positive finding. However, this will need to be
discerned through prospective studies that have the ability to use more precise measures of
kidney function. For example, future investigations should consider measuring
microalbuminuria as part of screening for early renal dysfunction, since microalbuminuria
has been shown to characterize the early stages of SCD nephropathy in both children and
adults (Becton, et al 2010, Guasch, et al 2006). Another future avenue for investigation is to
determine whether or not MYH9 variation can help explain the increased prevalence of
ESRD among African Americans with sickle cell trait (Derebail, et al 2010)
In summary, our study brings us closer to understanding the complex gene/gene and gene/
environment interactions that affect clinical outcomes of SCD. Further studies with
independent data sets are now needed to confirm this association, to identify more of the
genes involved, and to test new therapeutic approaches to prevent or treat SCD nephropathy.
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(a) Structure of the APOL1 and MYH9 genes. Genotyped SNPs are shown in different
colors: black – non-coding; red – coding. SNPs defining the MYH9 risk haplotype, along
with their risk alleles, are indicated below the gene structure diagram. * = Nominally
significant at p<0.05; ** = Significant at threshold adjusted for multiple testing of p<0.0025.
(b) LD map for the 28 SNPs typed shown. Darker squares represent stronger LD.
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